-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 5th, Amgen announced the latest results of its investigational anti-FGFR2b monoclonal antibody therapy bemarituzumab in a phase 2 clinical trial at the ASCO annual meeting.
Gastric cancer is the fourth leading cause of cancer deaths in the world.
Bemarituzumab is a monoclonal antibody against FGFR2b.
▲The mechanism of action of bemarituzumab (picture source: Five Prime official website)
In this phase 2 clinical trial, the bemarituzumab combination therapy was more effective in a subgroup of patients with >10% of tumor cells overexpressing FGFR2b.
In terms of safety, the number of adverse events in the bemarituzumab+ chemotherapy group (100%) and the chemotherapy group (98.
Dr.